Guardant Health Analyst Price Targets

Guardant Health Inc

GHNASDAQ

Trade with Public

$158.60

-7.28-4.39%

Dern. MÀJ: Oct 16, 5:41 PM

$156.68

-9.20-5.54%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Guardant Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Guardant Health (GH).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

25Buy

Consensus RatingBuy# Analysts25Avg. Consensus PT$168Upside to Avg. PT+7.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$185→$200
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$200→$220
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$190→$200
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$175→$225
Sep 8, 2026	Rothschild & Co	Jamie Clark	Initiate	Buy	$203
Sep 2, 2026	BTIG	Mark Massaro	Maintained	Buy	$195
Aug 4, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$135→$193
Aug 4, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$170→$195
Aug 4, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$175→$185
Aug 3, 2026	Stifel	Daniel Arias	PT Raise	Buy	$130→$180
Jul 31, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$185→$200
Jul 31, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$175→$200
Jul 31, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$185→$195
Jul 31, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$200→$210
Jul 31, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$150→$200
Jul 31, 2026	BTIG	Mark Massaro	PT Raise	Buy	$190→$195
Jul 16, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$160→$190
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$135→$205
Jul 9, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$130→$175
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Buy	$150→$215

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.

Benzinga Newsdesk

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.

Benzinga Newsdesk

Guardant Health Inc

Guardant Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Guardant Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

People Also Watch

People Also Watch

Guardant Health Inc

Guardant Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PROBarclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PROGuggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PROUBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRORothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PROBTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Guardant Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PROBarclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PROGuggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PROUBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRORothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PROBTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target